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Introduction {#sec001}
============

Lung cancer is the leading cause of cancer death\[[@pone.0170901.ref001]\]~.~ Approximately 80% to 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Of these cases, over 60% of patients require radiation therapy (RT) during the course of the disease\[[@pone.0170901.ref002]\]. In recent years, despite modern radiotherapy technologies, such as three-dimensional conformal radiation therapy (3D-CRT) and/or intensity modulation radiation therapy (IMRT), one treatment of 2 Gy is given daily 5 days per week for a total of 60+ Gy over 6+ weeks. The 5-year survival rate of NSCLC is approximately 15--20%\[[@pone.0170901.ref003]\]. Recent studies have shown that the incidence of severe radiation-induced lung toxicity (RILT) (Grade ≥ 3) is approximately 2.2--18%, and the incidence of radioactive esophagitis (Grade ≥ 3) is approximately 12.5%-34%\[[@pone.0170901.ref004],[@pone.0170901.ref005],[@pone.0170901.ref006]\]. This may be due to unknown changes in the tumor and normal tissues biological characteristics and function during therapy. Recent studies have demonstrated that, compared with prior to radiotherapy, the tumor size, shape, position, biological activity and normal tissue function may change and even cause tumor target and important organ damage in the middle of RT. Therefore, it is necessary to make comprehensive assessments during RT.

Dose escalation has been shown to be an effective means of increasing local control. Every 1 Gy above the conventional prescription dose could improve the 3- to 5-year survival rate by approximately 1% and decrease the hazard of death by 3%\[[@pone.0170901.ref007]\]. However, the potential high risk of radiation toxicity limits dose escalation\[[@pone.0170901.ref004],[@pone.0170901.ref005],[@pone.0170901.ref008],[@pone.0170901.ref009]\], and, thus, 3D-CRT and IMRT based on computerized tomography (CT) imaging could not improve the response significantly. Molecular imaging may be the best tool to obtain the dynamic and spatial biological features safely. In recent years, fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used in patients with NSCLC, such as for the diagnosis and staging of tumors, choice of treatment plan, assessment of treatment responses and delineation of radiotherapy tumor volumes. FDG-PET has enabled image-guided RT to assess the patient's position and biological characteristics for each treatment\[[@pone.0170901.ref010],[@pone.0170901.ref011],[@pone.0170901.ref012],[@pone.0170901.ref013],[@pone.0170901.ref014],[@pone.0170901.ref015],[@pone.0170901.ref016],[@pone.0170901.ref017]\]. While most studies have focused on imaging prior to or after RT, they have ignored tumor changes during RT. Adaptive RT, whereby the treatment plans are modified over the course of treatment to account for individual patient and tumor changes, is an emerging concept for improving local control while minimizing toxicity\[[@pone.0170901.ref018]\]. It would be preferable to acquire FDG-PET before and during treatment, which could provide an opportunity to adjust and optimize further therapy.

A small pilot study by Kong et al.\[[@pone.0170901.ref019]\] demonstrated that tumor activity was reduced during-RT (40--50 Gy), and during-RT, PET-metabolic tumor volumes (PET-MTVs) can be used to adapt the radiotherapy plans to provide radiation dose escalation (30102 Gy, mean 58 Gy) to more active malignancies. Meanwhile, it may reduce the normal tissue complication probability (NTCP) by 0.4--3% (mean, 2%)\[[@pone.0170901.ref020]\]. Stanford University (RSNA2008) has reported that at approximately two-thirds of the total dose during-RT (approximately 4 weeks), the FDG uptake was decreased and associated with a progression free survival rate.

Thus, the purpose of our study was to quantify the change in MTVs from baseline to during-RT and then explore the potential benefits of late-course adaptive plans compared to original plans by dose volume histogram (DVH) comparisons. If the changes can be predicted during treatment, the remaining treatment may be individualized accordingly.

Materials and Methods {#sec002}
=====================

Ethical approval {#sec003}
----------------

The study was approved by the Ethical Committee of the Shandong Cancer Hospital affiliated to Shandong University and has, therefore, been performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki. All patients provided written informed consent before the study.

Patients {#sec004}
--------

Adult patients with histologically confirmed stage II to III NSCLC (American Joint Committee on Cancer 2003) requiring definitive irradiation with chemotherapy based on the stage of the disease and medical condition were enrolled in this prospective study from March 2013 to October 2014 in the Shandong Cancer Hospital affiliated to Shandong University. Written informed consent was obtained from the subjects before enrollment. Patients with small cell lung cancer or mixed small cell/non-small cell tumor histology, who received pericardial effusion or were pregnant or lactating were excluded from the study.

^18^F-FDG PET/CT image {#sec005}
----------------------

FDG PET-CT images were acquired as previously described\[[@pone.0170901.ref021]\]. In this study, PET-CT scans were acquired within 1 week before RT (pre-RT) and during RT (during-RT) of approximately 40 Gy. PET-CT scans were evaluated qualitatively by both a nuclear medicine physician and a radiation oncologist and an objective quantification of FDG uptake in the region of interest (ROI).

PET-MTVs delineation {#sec006}
--------------------

There are multiple ways to define PET-MTVs. We elected to use an auto-segmentation method based on a fixed source/background ratio combined with CT anatomy based manual editing to delineate PET-MTVs, as illustrated in [Fig 1](#pone.0170901.g001){ref-type="fig"}. The specific delineation method can refer to what has been described in a previous study\[[@pone.0170901.ref022]\].

![PET-MTVs delineation and treatment planning.\
PET-MTVs, positron emission tomography-metabolic tumor volumes.](pone.0170901.g001){#pone.0170901.g001}

Treatment planning {#sec007}
------------------

PET/CT images were transferred to the treatment planning system (TPS, Varian Medical Systems, Palo Alto, CA, USA) via DICOM. The initial planning target volume (pre-PTV) was based on PET1MTVs. MTVs that were considered the gross tumor volume (pre-GTV) included the primary tumor and any involved hilar or mediastinal lymph nodes. Uninvolved lymph node regions were not included in the clinical target volume (CTV). The initial CTV (pre-CTV) consisted of the pre-GTV and approximately a 0.5 cm margin for microscopic extension. The pre-PTV consisted of the pre-CTV plus a minimal 0.5 cm margin for setup error plus an individualized margin for target motion if the motion was not controlled or the pre-GTV did not include the target motion. The same steps were performed on the first images of the treatment planning and the images taken after 40 Gy. The pre-PTV for the adaptive plan was the during-PTV, which was defined based on the during-RT PET/CT study and consisted of the PET2MTVs plus at least a 0.5 cm expansion. The PET2MTVs were auto-contoured using the same normalized threshold value (normalized to the mediastinal blood pool in the aortic arch) as was used to define the PET1MTVs, pre-GTV, pre-CTV and pre-PTV using the same motion management technique employed in the initial plan.

Radiation was delivered using a 3D-CRT or IMRT to match the planning constraints (mean lung dose to \<20 Gy and total lung V20 ≤35%, maximal spinal cord dose ≤45 Gy). An original plan, based on the baseline MTVs, and an adaptive plan, based on during-RT MTVs, were generated for each patient. Both phases of treatment were implemented by 2.0 Gy/fraction, 5 fractions a week. The dose was prescribed to the 90% isodose line with lung correction for inhomogeneity, which encompassed at least 95% of the PTV. The DVHs for lung, heart, esophagus and spinal cord were compared between the original plan at the prescribed dose 66 Gy and the composite plan at 66 Gy (original plan at 40 Gy plus the adaptive plan at 26 Gy).

The PET images were used only to provide an assessment of the metabolic tumor volume, and they were not incorporated quantitatively into the clinical treatment planning. All patients' prescribed treatment courses were carried out according to the original plan.

Statistical considerations {#sec008}
--------------------------

The primary objective of this study was to compare the changes in PET-MTVs between pre- and during-treatment and discuss the potential benefits of a late-course adaptive plan compared to the original plan by DVH comparison. SPSS 17.0 software was used to test statistical significance. The change in each individual PET-MTV during RT was compared to that of baseline and the different DVH for all the organs at risk (lung, heart, esophagus and spinal cord) between the original plan at the prescribed dose 66 Gy and the composite plan at 66 Gy (original plan at 40 Gy plus the adaptive plan at 26 Gy). Comparisons were assessed by a nonparametric test (Wilcoxon signed-rank test) or 2 tailed paired t-test. P-values equal to or less than 0.05 were considered statistically significant. Unless otherwise specified, the data are presented as the mean (95% CI).

Results {#sec009}
=======

Patient characteristics and treatment {#sec010}
-------------------------------------

Seventeen stage II to III NSCLC patients were enrolled in this study. Fourteen patients were male, and 3 patients were female. The median age was 64 years. Five patients had Stage II, and 12 patients had Stage III disease (characteristics are shown in [Table 1](#pone.0170901.t001){ref-type="table"}). All patients had FDG PET/CT scans within 1 week prior to the initiation of radiation therapy and after the delivery of approximately 40 Gy (during-RT).

10.1371/journal.pone.0170901.t001

###### Patient Characteristics.

![](pone.0170901.t001){#pone.0170901.t001g}

  Characteristics               Numbers of patients
  ----------------------------- ---------------------
  **Age, years**                
      ≤70                       14
      \>70                      3
  **Gender**                    
      Male                      14
      Female                    3
  **KPS**                       
      ≤80                       3
      \>80                      14
  **Smoker**                    
      Yes                       15
      No                        2
  **Type of cancer**            
      Central                   10
      Peripheral                7
  **Histology**                 
      Adenocarcinoma            3
      Squamous carcinoma        10
      Not otherwise specified   4
  **Clinical stage**            
      Ⅱ                         5
      Ⅲ                         12
  **Chemotherapy**              
      Yes                       17
      No                        0

KPS, Karnofsky.

Changes in PET-MTVs during RT {#sec011}
-----------------------------

The changes in PET-MTVs during RT are presented in [Table 2](#pone.0170901.t002){ref-type="table"}. Examples of patients with MTV reductions are presented in [Fig 2](#pone.0170901.g002){ref-type="fig"}. For the entire group of seventeen patients, compared to the baseline values, the volume of PET-MTVs were reduced significantly at the time of approximately 40 Gy (pre-RT 136.2±82.3 ml vs. during-RT 64.7±68.0 ml, p = 0.001).

![Comparison of MTVs pre-RT and dur-RT.\
MTVs, metabolic tumor volumes; RT, radiotherapy.](pone.0170901.g002){#pone.0170901.g002}

10.1371/journal.pone.0170901.t002

###### MTV and parameters of DVH for all the organs at risk.

![](pone.0170901.t002){#pone.0170901.t002g}

  Organs            Parameters                                           Original plan                                       Composite plan                                   p value
  ----------------- ---------------------------------------------------- --------------------------------------------------- ------------------------------------------------ ---------
  **MTV**           \(ml\)                                               136.2±82.3[\*](#t002fn001){ref-type="table-fn"}     64.7±68.0[\*](#t002fn001){ref-type="table-fn"}   0.001
  **Total-lung**    V5                                                   58.90%                                              48.60%                                           \<0.001
  V10               44.50%                                               34.60%                                              \<0.001                                          
  V13               37.40%                                               30.50%                                              \<0.001                                          
  V15               33.90%                                               27.80%                                              \<0.001                                          
  V20               27.80%                                               23.30%                                              \<0.001                                          
  V25               23.70%                                               19.20%                                              \<0.001                                          
  V30               20.40%                                               15.60%                                              \<0.001                                          
  D~mean~ (cGy)     1663.0±568.9[\*](#t002fn001){ref-type="table-fn"}    1444.6±547.4[\*](#t002fn001){ref-type="table-fn"}   \<0.001                                          
  **Heart**         V10                                                  50.20%                                              38.20%                                           0.002
  V20               34.60%                                               28.10%                                              0.002                                            
  V30               25.60%                                               21.90%                                              0.001                                            
  V40               18.20%                                               15.10%                                              0.001                                            
  V50               13.30%                                               9.50%                                               0.001                                            
  V60               6.50%                                                4.40%                                               0.001                                            
  D~mean~ (cGy)     1937.4                                               1545.8                                              0.001                                            
  **Esophagus**     V35                                                  39.40%                                              35.70%                                           0.001
  V40               38.30%                                               32.50%                                              0.001                                            
  V50               31.30%                                               25.90%                                              0.001                                            
  V55               29.50%                                               21.60%                                              0.001                                            
  V60               26.90%                                               17.80%                                              0.001                                            
  D~max~ (cGy)      7241.2                                               7186.9                                              0.001                                            
  D~mean~ (cGy)     2528.2±1136.3[\*](#t002fn001){ref-type="table-fn"}   2268.3±1196[\*](#t002fn001){ref-type="table-fn"}    0.04                                             
  **Spinal-cord**   D~max~ (cGy)                                         4,199.7                                             4,133.9                                          0.004

\*: Mean ± standard deviation.

MTV, metabolic tumor volumes; DVH, dose volume histogram.

Different DVHs between the original plan and composite plan {#sec012}
-----------------------------------------------------------

For all the patients, we completed RT planning before and during radiotherapy. The composite plan of the original plan at 40 Gy plus the adaptive plan at 26 Gy resulted in better DVH for all the organs at risk than the original plan at 66 Gy (p\<0.05), including V5 (48.6% vs. 58.9% p\<0.001), V10 (34.6% vs. 44.5% p\<0.001), V13 (30.5% vs. 37.4% p\<0.001), V15 (27.8% vs. 33.9% p\<0.001), V20 (23.3% vs. 27.8% p\<0.001), V25 (19.2% vs. 23.7% p\<0.001), V30 (15.6% vs. 20.4% p\<0.001) and the mean dose for the total lung (1444.6±547.4 cGy vs. 1663.0±568.9 cGy p\<0.001). V10 (38.2% vs. 50.2% p = 0.002), V20 (28.1% vs. 34.6% p = 0.002), V30 (21.9% vs. 25.6% p = 0.001), V40 (15.1% vs. 18.2% p = 0.001), V50 (9.5% vs. 13.3% p = 0.001), V60 (4.4% vs. 6.5% p = 0.001) and the mean dose for the heart (1545.8 cGy vs. 1937.4 cGy p = 0.001). V35 (35.7% vs. 39.4% p = 0.001), V40 (32.5% vs. 38.3% p = 0.001), V50 (25.9% vs. 31.3% p = 0.001), V55 (21.6% vs. 29.5% p = 0.001), V60 (17.8% vs. 26.9% p = 0.001), the maximum dose (7186.9 cGy vs. 7,241.2 cGy p = 0.001) and the mean dose for the esophagus (2268.3±1196 cGy vs. 2528.2±1136.3 cGy p = 0.04), and the maximum dose for the spinal-cord (4133.9 cGy vs. 4199.7 cGy p = 0.004). The compared parameters collected from DVH for the original plan and the composite plan are listed in [Table 2](#pone.0170901.t002){ref-type="table"}.

Discussion {#sec013}
==========

Radiotherapy is the main local treatment for patients with inoperable stage II-III NSCLC, and an adequate dose is essential for treatment success as increased radiation doses have been associated with reduction in the risk of death\[[@pone.0170901.ref007]\]. However, most patients with stage III NSCLC cannot receive an adequate dose for tumor control without exceeding the "safe" dose limits of the adjacent critical structures, such as the lung, esophagus, heart and spinal cord. An accurate definition of a target is crucial for the delivery of high-precision radiotherapy in NSCLC. We used FDG-PET to assess the tumor and normal tissues biological characteristics and function during RT. Meanwhile, FDG-PET could play an important role in lymph node staging by accurately showing positive nodes. However, PET helped to differentiate tumors and collapsed lungs, allowing a more accurate radiation volume of the lung. To redirect the remaining treatment, FDG PET-CT scans were repeated at approximately two-thirds of the total dose during-RT (approximately 40 Gy).

This study demonstrated that PET-MTVs may be reduced significantly at the time of approximately 40 Gy during RT (pre-RT 136.2±82.3 ml vs. during-RT 64.7±68.0 ml, p = 0.001), and late-course adaptive radiotherapy may be an effective way to reduce the dose volume to the organs at risk in patients with NSCLC, which deserves further study. In a previous study, Mahasittiwat et al.\[[@pone.0170901.ref022]\] found that the mean PET-MTVs were 43.4 cc (28.2--58.5 cc) and 17.9 cc (10.0--25.7 cc) on pre-RT and during-RT (approximately 45 Gy) scans, respectively, and the mean reduction in PET-MTVs was 32.2 cc (20.8--43.7 cc, p\<0.001). In the course of RT (40 Gy\~50 Gy), FDG-PET/CT activity decreased\[[@pone.0170901.ref020]\], and the tumor volume was significantly reduced\[[@pone.0170901.ref007],[@pone.0170901.ref023],[@pone.0170901.ref024],[@pone.0170901.ref025],[@pone.0170901.ref026]\]. Similar results have been obtained in previous studies. A study by Fox et al.\[[@pone.0170901.ref027]\] indicated that the GTV had a median reduction during RT (24.7% at 30 Gy, 44.3% at 50 Gy). Ding et al.\[[@pone.0170901.ref025]\] carried out an analogous study that demonstrated that the tumor volumes regressed in 84 (96.6%) patients and increased in 3 (3.4%) patients after 40 Gy; the mean GTV and PTV reduction was 38% (range, 213--95%) and 30% (range, 25--95%). Guckenberger et al.\[[@pone.0170901.ref028]\] studied the tumor changes in 13 patients with NSCLC, and they found continuous tumor regression by 1.2% per day as measured by CT images, which was in good agreement with the results presented by Kupelian's research\[[@pone.0170901.ref029]\] and Everitt's research\[[@pone.0170901.ref026]\].

PET-MTVs were significantly reduced in RT, such that it may directly lead to improvements in lung function, toxicity rates and dose escalation. While we still do not know if the target volume reductions are warranted when GTV shrinkage has occurred during RT\[[@pone.0170901.ref029],[@pone.0170901.ref030],[@pone.0170901.ref031]\], some physicians advocated an approach in which the target volume remained constant due to concerns of residual microscopic disease. In our study, the composite plan resulted in better DVH for all the organs at risk that were evaluated compared to the original plan at 66 Gy (p\<0.05), including V~5~, V~10~, V~15~, V~20~, V~25~, V~30~ and the mean dose (p\<0.05) for the total lung; V~10~, V~20~, V~30~, V~40~, V~50~, V~60~ and the mean dose (p\<0.05) for the heart; V~35~, V~40~, V~50~, V~55~, V~60~, the maximum dose and mean dose (p\<0.05) for the esophagus; and the maximum dose (p\<0.05) for the spinal-cord. Ding et al.\[[@pone.0170901.ref021]\] found that during RT (40 Gy), after modifying the RT plan, the dose volume parameters of V20 of the lung, V60 of the esophagus, V45 of the heart, V65 of the heart in the composite plan (40 Gy to the PTV with a subsequent 20--28 Gy-boost to the shrunken PTV) were higher than original plan (delivering the same dose to the initial PTV without shrinking the field; p\<0.05). Feng et al.\[[@pone.0170901.ref020]\] performed a pilot study in which 14 patients with NSCLC underwent PET-CT scans pre-RT and during RT. They found that this method allowed for a mean dose escalation of 58 Gy or a reduction in NTCP of up to 3% in patients with a reduction in tumor size. Similar results could be seen in another study by Gillham et al.\[[@pone.0170901.ref032]\].

To the best of our knowledge, we aimed to examine the MTVs from baseline to the late-course of RT by FDG PET-CT and discuss the potential benefits of late-course adaptive plans compared to the original plans by DVH comparisons. There are several limitations to this study. (1) As the sample size was small, further study with a larger number of patients is needed to validate the present findings. (2) This was only a planning study, we do not know if this adaptive plan affected tumor control or increased the rate of tumor recurrence with the narrowed treatment fields. All these limitations require further evaluation in future studies.

Conclusion {#sec014}
==========

This study indicated that PET-MTVs may be reduced significantly at the time of approximately 40 Gy during RT, and late course adaptive radiotherapy may be an effective way to reduce the dose volume to the organs at risk. This could reduce radiation-induced injury in patients with NSCLC. More prospective studies on FDG PET-CT scans are ongoing in our institution.

Supporting Information {#sec015}
======================

###### MTVs of ^18^F-FDG PET-CT in original plans and composite plans.

(XLS)
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Click here for additional data file.

###### Parameters of DVH for all the organs at risk in original plans and composite plans.

(XLS)

###### 

Click here for additional data file.
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